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Background: Myeloid sarcomas (MS) are rare extramedullary tumors composed of blasts of myeloid lineage that either precede, fol-
low or present concomitantly with acute myeloid leukaemia (AML) or myeloproliferative neoplasms. The diagnosis of MS is espe-
cially challenging in patients without an antecedent history of leukemia. Methods: We present 2 cases of intraoral MS that presented 
as de novo lesions. A detailed review of cases of intraoral MS that either preceded or presented along with leukemia has been done with 
emphasis on diagnostic criteria used. Results: Two male patients aged 28 and 5 years presented with MS with one patient presenting 
with concomitant AML. A combination of morphological and immunohistochemical methods was used for diagnosis. A thorough review 
of world literature revealed 44 cases of intraoral MS that presented as de novo lesions. Conclusion: Intraoral MS is a rare tumor with 
poor prognosis. It may be diagnostically challenging due to its protean clinical manifestations and histological overlap with other tumors.
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Myeloid sarcoma (MS) is a pathologic diagnosis for 
an extramedullary proliferation of blasts of one or more 
myeloid lineages that leads to effacement of the tissue 
architecture in which it is found [1]. Originally called 
chloromas due to the greenish color on gross exami-
nation attributed to production of myeloperoxidase, 
it has subsequently undergone numerous changes 
in nomenclature including granulocytic tumor, extra-
medullary myeloid tumor and myeloblastoma. This 
change in nomenclature reflects the various facets 
of the historical evolution of this tumor corresponding 
with molecular and cytogenetic understanding of the 
neoplasm.
MS is usually observed in a setting of acute myeloid 
leukemia (AML), myeloproliferative neoplasms and 
mixed myelodysplastic/myeloproliferative neoplasms 
(50%). Appearance of MS in an AML patient in remis-
sion is an indication of relapse. Rarely MS has pre-
sented after allogenic stem cell transplantation [2, 3]. 
15–35% of MS cases are detected concomitantly with 
AML, however, it is the remaining 25–27% that precede 
AML that create a diagnostic dilemma.
Intraoral MS is an exceedingly rare lesion with only 
about 75 cases reported since its first description 
in 1811. Almost all intraoral sites can be involved includ-
ing the jaws, gingiva, hard and soft plate, tonsils, maxil-
lary sinus, tongue and lips. Here we present two cases 
of intraoral MS along with review of world literature. 
Emphasis has been placed on the diagnostic criteria 
used by various authors. We also present differential 
diagnosis, approaches to diagnosis and pitfalls in di-
agnosing MS when it precedes or is diagnosed with 
AML based on review of world literature.
CASE REPORTS
Case I
A 28 year old monoplegic male presented with 
a progressively enlarging swelling on left side of face, 
since 5–6 months (Fig. 1, a). He had undergone ex-
traction of 36.2 months ago due to mobility. Physical 
examination revealed ill defined bony hard swelling 
extending from the left ala tragus line up to lower bor-
der of mandible with involvement of ramus and angle 
of mandible. Intraorally, expansion on buccal aspect of 
#34 to #37 and healed extraction socket of #36 were 
noted. Orthopantomogram showed ill defined mixed 
radiolucent and radiopaque lesion with respect to left 
angle of mandible extending up to the ramus of man-
dible (Fig. 1, b). Laboratory studies including complete 
blood count and serum chemistry were within normal 
range.
Incisional biopsy was performed via intraoral 
approach. Histopathological examination revealed 
a diffuse infiltration of large atypical cells with vesicu-
lar nuclei with predominance of crushed nuclei. The 
atypical cells were seen infiltrating in between and 
splaying the muscle fibers (Fig. 1, c). A basic immu-
nohistochemical panel consisting of pancytokeratin, 
vimentin, S100, CD45, and desmin was performed. 
The tumor cells were positive for CD45 (Fig. 1, d) 
and a presumptive diagnosis of non-Hodgkin’s lym-
phoma was made. However, the cells were negative 
for CD3 and CD20. The H&E slides were re-examined 
and a population of large cells containing eosinophilic 
granules (Fig. 1, e) was seen intermingling with the 
tumor cells with areas of degranulation.
Based on all previous investigations and histo-
pathological findings, anti-myeleoperoxidase antibody 
(anti-MPO) staining (Fig. 1, f) was performed which 
showed strong diffuse positivity. Bone marrow biopsy 
was within normal limits. A diagnosis of MS in the ab-
sence of AML was thus made.
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Patient underwent induction chemotherapy with cy-
tarabine and idarubucin with lesion regression. He has 
remained in remission for 14 months after diagnosis 
with normal blood counts.
Case II
A 5 year old male child was referred to our Centre 
by a private dentist with rapidly progressing mildly 
tender swelling in left posterior mandibular region 
(Fig. 2,  a), since last 10 days. History of trauma was 
elicited 25 days prior to commencement of swelling 
and there was no history of any systemic disease. 
Examination revealed a well defined bony hard swell-
ing with expansion of buccal and lingual cortices. The 
left deciduous molars were mobile and displaced due 
to the swelling (Fig. 2, b). A large area of ulceration 
was noted on the linguo-occlusal aspect. Orthopan-
tomogram showed an ill defined mixed radiolucent 
radiopaque lesion causing resorption of molar roots 
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Fig. 1. Clinical, radiographic, histological and immunohistochemical findings of Case #1: a — extra oral photograph showing dif-
fuse swelling over left mandible; b — orthopantogram showing poorly defined mixed radiolucent-radio opaque mottled lesion with 
partially healed socket of #36; c — microphotograph showing tumor cells invading in between and splaying muscle fibers (H & E, 
× 100); d — microphotograph showing diffuse positivity for CD45; e — higher magnification showing granular eosinophilic myelocytes 
(arrow) intermingling with immature tumor cells (H & E, × 1000); f — microphotograph showing strong positivity for MPO
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Fig. 2. Clinical, radiographic and histological findings of Case #2: a — extra oral photograph showing swelling over left angle of mandible 
that showed rapid expansion over a period of 1 week post incisional biopsy (f); b — intraorally, swelling with expansion of buccal and lingual 
cortices and ulcer over the linguo-occlusal surface covered by grayish pseudomembrane was observed at first visit; c — orthopantogram 
showing ill defined radiolucent lesion involving left posterior mandible causing resorption of molar roots (note the sunburst pattern at the 
periphery); d — microphotograph with pleomorphic round to spindled tumor cells (H & E, × 100); e — microphotograph showing immature 
tumor cells with varying degree of pleomorphism and mitotic activity (H & E, × 1000); f — 1 week post biopsy, a massive increase in swell-
ing; g — 1 week post biopsy, the lesion showing massive expansion with an irregular, granular and necrotic appearance
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and a periosteal reaction giving a sunburst appear-
ance (Fig. 2, c). Other than decreased hemoglobin 
level of 10.5 gm/dl, all other hematological parameters 
were within normal limits.
An incisional biopsy was subsequently performed 
along with extraction of the mobile teeth. Biopsy 
showed diffuse infiltration of predominantly round cells 
effacing the tissue architecture. The cells had sparse 
to moderate eosinophilic cytoplasm with prominent 
nuclei. Abundant mitotic figures were seen with mito-
ses ranging from 5–6 per high power field (Fig. 2, d, e).
Based on H & E sections, Ewing’s sarcoma, em-
bryonic rhabdomyosarcoma, and neuroblastoma were 
included in the differential diagnosis. The tumor cells 
were negative for vimentin, desmin, CD99, CD45 and 
NSE. In the mean time, the patient reported with 
a massive increase in swelling (7 days post biopsy) 
(Fig. 2, f, g). 
A peripheral smear was repeated and numerous 
immature blasts including myeloblasts, and band 
forms were observed (Fig. 3, a). Immunohistoche-
mistry was then done using anti-MPO (Fig. 3, b) and 
anti-CD34 (Fig. 3, c). The tumor cells were diffusely 
positive for MPO and focally positive for CD34. The 
lesion was thus diagnosed as MS. Subsequently, bone 
marrow biopsy was performed that showed marrow 
involvement with atypical cells with high nuclear-to-
cytoplasmic ratio, focal nuclear convolutions and 
moderate to scant cytoplasm (Fig. 3, d). These atypical 
cells constituted more than 50% of marrow population. 
Strong MPO activity was also noticed in these atypical 
cells. MS presenting with AML was the final diagno-
sis. The left deciduous second molar was decalcified 
and showed dense diffuse infiltration by tumor cells 
completely obliterating the pulpal architecture (Fig. 4).
Patient underwent chemotherapy with cytarabine 
followed by successful lesion regression. He is cur-
rently in remission, one year post diagnosis.
A thorough search of world literature revealed 
77 cases of intraoral MS, of which 44 lesions either 
preceded or presented concomitantly with leukemia. 
Diagnostic criteria used for these lesions (MS present-
ing with or preceding leukemia) have been compiled 
in Table 1 [1–46].
DISCUSSION
The diagnosis of MS can be a clinical challenge 
when there is no antecedent myeloid neoplasm. It has 
been reported that up to 27% cases present de novo 
and there may be a lag of up to 10 months between 
first presentation and bone marrow involvement [45, 
46]. A high degree of clinical suspicion thus becomes 
mandatory in order to establish diagnosis. In a study 
of 26 MS cases by Menasce et al. [47], 14 were initially 
misdiagnosed, all 14 being without prior history of leu-
kemia or myeloproliferative disorders. Further Byrd 
et al. [48] in their study found that up to 46% of pub-
lished isolated cases were misdiagnosed, commonly 
as large cell lymphomas. The differential diagnosis 
of MS is quite large and clinical features such as age 
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Fig. 3. Cytological and immunohistochemical findings 
of Case #2: a — peripheral smear showing presence of band 
forms and myeloblasts (Giemsa, × 100); b — diffuse positivity 
for MPO seen in all tumor cells (× 100); c — focal positivity for 
CD34 observed in some tumor cells (× 100), d — bone marrow 
aspirate showing numerous blast cells (Giemsa, × 100)
Experimental Oncology 39, 78–85, 2017 (March) 81
along with presence of a preexisting or concurrent 
myeloid neoplasm must be factored in.
The pathogenesis of MS has been attributed 
to an aberrant homing signal for the leukemic blast 
cells rather than their localization within the bone 
marrow [1]. Studies have shown that this homing and 
retention of the blasts may be mediated by different 
chemokine/chemokine receptor activations and the 
invasive potential of the cells is due to interactions 
between MMPs and integrins [49–51].
The clinical features of oral MS can be extremely 
variable and nonspecific. Patients may present with 
swelling, sore throat, purulent discharge, jaw pain, 
mobile teeth, sinus pain, tonsillar enlargement and 
lymphadenopathy amongst others [41]. MS has 
been reported at almost all intraoral sites with the 
mandible accounting for the maximum number 
of cases (35%). The most common site for extraoral 
MS is the skin (leukemia cutis) where it presents 
as multiple papules, plaques and nodules [34]. 
Radiographically, intraosseous oral lesions vary 
from innocuous appearing periapical granulomas/
abscesses and superficial bony erosion to massive 
destructive expansile lesions involving large areas 
of the jaw [1, 9, 11, 52]. Periosteal reactions around 
the lesion and sinus haziness are some of the other 
reported findings.
Morphologically, MS classically presents as a tu-
mor composed of immature cells namely myeloblasts, 
monoblasts and rarely promyelocytes that partially 
or completely efface the overall architecture of the 
tissue involved. The cells show scant cytoplasm with 
multilobed round to oval nuclei, fine or dusty nuclear 
chromatin and one or two small basophilic nucleoli [53, 
54]. MS were historically divided into granulocytic 
sarcoma and monocytic sarcoma. Pileri et al. [45] 
in 2007 further classified GS into three variants 
as per the morphological type. Blastic variant shows 
predominance of myeloblasts with little evidence 
of maturation and no cytoplasmic granules, immature 
type (intermediate grade) consists of myeloblasts, 
promyelocytes and eosinophilic myelocytes and dif-
ferentiated or mature type shows promyelocytes, and 
more mature cells with abundance of eosinophils. 
According to this classification, Case #1 belongs 
to the differentiated type and Case #2 to the blastic 
type. However, the cytomorphologic classification 
has no bearing on prognosis and is hence clinically 
irrelevant [47, 55].
With increase in cytogenetic and molecular under-
standing of these tumors, the abovementioned mor-
phological distinctions seem less relevant. At the same 
time, sufficient knowledge regarding the immunohis-
tochemical makeup of the various subtypes may prove 
critical in establishing diagnosis. A number of studies 
describing the immunophenotype of MS have shown that 
the tumor can show features of any myeloid lineage and 
often may show multiple lineage expression in the same 
tumor [34, 53]. A number of enzyme cytochemical stains 
such as myeloperoxidase, sudan black B, chloracetate 
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Fig. 4. Decalcified section of left permanent first molar (Case #2) showing diffuse infiltration and effacement of pulpal architecture 
by tumor cells: a — H&E, × 20; b — H&E, × 40; c — H&E, × 40; d — H&E, × 400
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Table 1. Diagnostic criteria used for intraoral MS preceding or presenting with leukemia
No. Authors/Reference Year Age/Sex Location
Type of ma-
lignancy Diagnosis based on:
Marrow sta-
tus at the 
time of di-
agnosis
Time to leukaemia  
diagnosis
1 Wiernick et al. [4] 1970 35/F Cheek AML H & E Uninvolved 10 months after MS
2 Brooks et al. [5] 1974 8/M Maxillary sinus AML H & E Uninvolved 4 years
3 Hansen et al. [6] 1982 83/F Maxilla AML NA Uninvolved 3 months after MS
4 Conran et al. [7] 1982 2/F Mandible None H & E
Ultrastructural analysis
Uninvolved DF
5 Takagi et al. [8] 1983 25/F Mandible AML IHC — MPO Uninvolved 1 year 6 mos after MS
6 Reichart et al. [9] 1984 35/F Mandible AML, pro-
myelocytic
CS — chloracetate esterase Uninvolved 3 months after MS
7 Castella et al. [10] 1984 89/F Hard palate None CS — chloracetate esterase
Ultrastuctural analysis
DF Died of unrelated 
cause
8 Timmis et al. [11] 1986 52/M Mandible LL CS — Sudan black, chloracetate esterase
IHC — HLA, Leu-M3
Ultrastructural analysis
Involved Diagnosed with MS
9 Ficarra et al. [12] 1987 67/F Hard palate AML CS — chloracetate esterase 1 year 3 mos after MS
10 De Vicente  
Rodriquez et al. [13]
1990 56/M Left mandible AML CS — chloracetate esterase
IHC — lysozyme
Involved Diagnosed with MS
11 Eisenberg et al. 
[14]
1991 33/M Multiple sites None CS — Sudan black, MPO, α-naphthyl buty rate 
esterase
Uninvolved DF
12 Stack et al. [15] 1994 70/M Mandible CML CS — chloroacetate esterase; IHC — antilyso-
zomal peroxidase
Involved Diagnosed with MS
13 Roth et al. [16] 1995 47/M Gingiva AML NA NA NA
14 Lynch et al. [17] 1998 86 /F Maxillary gingiva AML IHC — MPO Uninvolved 2 years 5 mos after MS
15 Tong et al. [18 ] 2000 76 /F Maxillary gingiva AML IHC — MPO Uninvolved 7 months
16 Amin et al. [19] 2002 58/M Hard palate AML IHC — CD34 (weak)
FC — HLA-DR, CD11c, CD13, CD15, CD34, TdT
CG – trisomy 13 (47,XY,+13)
Involved Diagnosed with MS
17 Jordan et al. [20] 2002 62/F Mandible AML CS — chloracetate esterase
IHC — CD43, MPO, CD15
CG — normal
Uninvolved 6 weeks
18 Antmen et al. [21] 2003 12/F Gingiva AML IHC — MPO, lysozyme Uninvolved Few weeks after MS
19 Stoopler et al. [22] 2004 50/M Multiple sites AML IHC — LCA, CD43, CD34 (rare) Involved Diagnosed with MS
20 Colella et al. [23] 2005 62/F Maxillary gingiva AML IHC — MPO, lysozyme, CD45, CD68 Uninvolved Few weeks after MS
21 Koudstaal 
et al. [24]
2006 36/M Hard palate AML IHC — CD45, CD43, HLA-DR, CD4 (weak)
FC — CD117, CD56, CD13, HLA-DR, CD45, 
CD33 (weak)
CG — abnormal
Uninvolved 2 years
22 Goteri et al. [25] 2006 84/F Hard palate None IHC — CD45, CD43, CD34, MPO, CD68 Uninvolved DF
23 Yinjun et al. [26] 2006 44/F Gingiva None IHC — MPO, CD68
CG — trisomy 21
Uninvolved DF
24 Yoon et al. [27] 2006 63/M Gingiva AML IHC — CD117, MPO Involved Diagnosed with MS
25 Matsushita 
et al. [28]
2007 50/M Maxillary gingiva AML IHC — MPO, CD43 Involved Diagnosed with MS
26 Mohmedbhai 
et al. [29]
2008 45/M Tongue AML IHC — CD45, MPO, CD68
FC — MPO, CD33, CD117
CG — t(15;17) (q22;q12)
Involved Diagnosed with MS
27 Kim et al. [30] 2009 4 /F Mandible AML IHC — MPO, CD34, CD43, CD79a,
FC — CD13, CD33, CD38, CD117, HLA-DR, MPO
Involved Diagnosed with MS
28 Lu et al. [31] 2009 63/F Maxillary gingiva AML IHC — MPO, CD34, CD3 (rare), CD20 (rare) Involved Diagnosed with MS
29 Lu et al. [31] 2009 39/F Maxilla None IHC — MPO, CD34 Uninvolved DF
30 Papamanthos 
et al. [32]
2010 70/F Mandible AML IHC — CD43, lysozyme, MPO Involved Diagnosed with MS
31 Qiu et al. [33] 2010 16/F Condyle AML NR Involved Diagnosed with MS
32 Klco et al. [34] 2011 39/M Maxillary gingiva AML IHC — MPO, CD117, CD4, CD34 Uninvolved DF
33 Colović et al. [35] 2011 55/F Mandible None (HIV) IHC — CD117, CD45, CD68, lysozyme, 
CD13 (weak)
Uninvolved Dead at 8 months  
(HIV related sepsis)
34 Seema et al. [36] 2011 5/M Mandible AML IHC — MPO, TdT Involved Diagnosed with MS
35 Mei et al. [37] 2011 56/M Multiple None IHC — CD34, CD45, CD56, CD117, MPO Uninvolved DF
36 Yamashita et al. 
[38]
2012 1/M Mandible AML IHC — CD45
FC — CD33, CD65, MPO
Involved Diagnosed with MS
37 Kurdoğlu et al. [39] 2013 29/F Gingiva AML IHC — CD117, MPO NR NR
38 Guastafierro 
et al. [40]
2013 56/F Maxillary gingiva None (pleu-
ral effusion)
IHC — CD45, CD68, lysozyme, MPO Uninvolved Died due to other 
causes
39 Zhou et al. [41] 2013 77/F Tongue MDS CS — chloracetate esterase
IHC — CD4, CD1c, CD33, CD43, CD68, CD117, 
CD163, MPO, lysozyme
CG — 47,XX,+8[20]
Involved Diagnosed with MS
40 Zhou et al. [41] 2013 55/M Mandible CML IHC — MPO, CD43
CG — 46,XY,t(9;22) (q34;q11) [20]
Involved Diagnosed with MS
41 Zhou et al. [41] 2013 47/F Tonsil AML IHC — CD4, CD11c, CD33, CD43, CD45, CD68, 
CD117, MPO, lysozyme, CD163
CG — normal
Involved Diagnosed with MS
42 Sharma et al. [42] 2014 9/M Maxillary sinus DF IHC — CD31, MPO, vimentin, CD99 Uninvolved DF
43 Ponnam et al. [43] 2014 45/F Mandible NA IHC — CD45, CD68, CD117, MPO NR NR
44 Moshref et al. [44] 2014 45/M Multiple sites DF (MI) IHC — CD45, C-Kit Uninvolved Died due to MI after 
10 months
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esterase, α-naphthyl acetate esterase and α-naphthyl 
butyrate esterase have also been described.
Although the immunohistochemical panel for 
MS is well established, diagnosis may still be difficult 
for tumors presenting in the absence of a known 
primary. CD43 and lysozyme having a high sensiti-
vity but low specificity are the most commonly used 
markers. Other routinely used markers include MPO, 
CD68 (KP-1 clone), CD34, CD45, CD117 and CD33. 
However, tumors of purely monocytic origin are nega-
tive for CD34, CD117 and MPO and positive for CD68, 
CD43, and CD33 [34, 53, 56].
A guide to the immunohistochemical differential 
diagnosis of MS is given in Table 2.
The most common differential diagnosis for MS in the 
adult population is non-Hodgkin’s lymphoma (T & B cell 
type) [47]. It is especially true for T cell neoplasms 
as MS may express many markers of T cell differentiation 
namely, CD2, CD4, CD7, CD43, and CD45. Immature 
MS with no evidence of differentiation is usually mis-
diagnosed as diffuse large B cell lymphoma which has 
thick nuclear membrane and basophilic nucleoli, unlike 
myeloblasts or monoblasts, which have thin nuclear 
membranes and pinpoint nucleoli [57]. The use of a com-
prehensive immunohistochemical panel including lyso-
zyme, MPO and CD68 thus becomes mandatory when 
dealing with such lesions. Other neoplasms that need 
to be differentiated are poorly differentiated carcinomas, 
melanomas and epitheloid sarcomas.
In pediatric population, differentiating MS from 
small round blue cell tumors such as Ewing’s, primitive 
neuroectodermal tumors, neuroblastoma and alveolar 
rhabdomyosarcoma may become challenging. As seen 
in the case reported here, the radiographic appear-
ance of a destructive radiolucent lesion surrounded 
by periosteal reaction giving a sun burst appearance 
may also favor a diagnosis of Ewing’s sarcoma. The 
expression of CD99 by a large number of nonmono-
cytic MS further impedes diagnosis. However, positive 
expression of CD43, lysozyme and MPO swings the 
diagnosis in favor of MS. While dealing with children 
and young adults, it is prudent to exclude Langerhans 
cell histiocytosis from the differential diagnosis. The 
grooved coffee bean like nuclei of Langerhan’s cells 
and abundance of eosinophils in the background 
is often seen in the monocytic MS [58].
Apart from immunohistochemistry, flow cytomet-
ric analysis using CD13, CD33, CD117 and MPO for 
non-monoblastic MS and CD14, CD163, and CD11c 
in monoblastic MS is well established when fresh tis-
sue is available [1]. Cytogenetic abnormalities have 
been reported in approximately 50% of the MS cases 
and mirror the cytogenetic changes associated with 
AML. Interestingly, de novo cases of MS may lack 
these abnormalities. Pileri et al. [45] through FISH 
demonstrated trisomy 8 and monosomy 7 as the most 
common abnormalities. Trisomy 8 and inv (16) as de-
termined by conventional cytogenetics was reported 
by Alexeiv et al. [59]. Pediatric patients having t(8;21) 
(q22;22) karyotypic abnormality have been shown 
to have a predilection for head and neck involvement 
including the orbit and CNS [60].
Molecular abnormalities in MS are not very well 
established. Mutations in nucleophosmin (NPM) 1 and 
No. Authors/Reference Year Age/Sex Location
Type of ma-
lignancy Diagnosis based on:
Marrow sta-
tus at the 
time of di-
agnosis
Time to leukaemia  
diagnosis
45 Present case 2016 28/M Left mandible DF IHC — CD45, MPO Uninvolved DF
46 Present case 2016 5/M Left mandible AML IHC — MPO, CD34 Involved Diagnosed with MS
Notes: CG — cytogenetics; CML — chronic myeloid leukemia; CS — cytochemical staining; DF — disease free; F — female; FC — flow cytometry; HIV — human 
immudeficiency virus; HLA — human leukocyte antigens; IHC — immunohistochemistry; LL — lymphoblastic lymphoma; M — male; MDS — myelodysplastic 
syndrome; MI — myocardial infarction; NA — not available; NR — not reported.
Table 2. Immunohistochemical differential diagnosis of MS
Antibody Specificity
MS Non-Hodg-kin’s lymphoma
Ewing 
sarco-
ma
Epithe-
loid sar-
coma
Poorly dif-
ferentiated 
carcinoma
Melano-
ma
Lan gerhans 
cell histio-
cytosis
Nonmono-
cytic
Mono-
cytic B cell T cell
CD43 T cells, myeloid cells, subset of B cells, T & B cell lymphomas +++ +++ ++ +++ − − − − −
Lysozyme Myeloid & monocyte/macrophage lineage cells +++ +++ − − − − − − −
MPO Myeloid lineage cells +++ − − − − − − − −
CD68 Monocyte/macrophage lineage cells ++ ++ − − − − − − −
CD34 Vascular progenitor cells, endothelial cells, interstitial 
cells of cajal, leukemic blasts, some soft tissue tumors
++ − − − − ++ − − −
CD45 T & B lymphocytes, monocytes, macrophages, mast 
cells & weakly on granulocytes
+ + +++ +++ − − − − −
CD117 Interstitial cells of cajal, germ cells, bone marrow stem 
cells, breast epithelium, melanocytes & mast cells
++ − − − − − − − −
CD33 Cells of myeloid lineage, some lymphoid cells ++ + − − − − − − −
CD3 T lymphocytes + − − +++ − − − − −
CD20 B lymphocytes − − +++ − − − − − −
CD99 Ewing sarcoma, primitive neuroectodermal tumor, 
periphe ral neuroepithelioma
+ − + ++ +++ − − − −
Others CD79a FLI1
S100
NSE
CK
INI-1
Vimentin
EMA
High & low 
weight CK
HMB 45
Melan A
S 100
CD1a
S100
Note: +++ strongly positive, ++ frequently positive, + rarely positive, — negative.
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its resultant aberrant cytoplamic expression have been 
reported in approximately 15% of MS patients [61]. The 
prevalence of Fms like tyrosine kinase-3 (FLT3) muta-
tions has been reported in a small subset of MS ca-
ses [62]. The significance of these mutations on the 
prognosis of MS patients is yet unknown.
With respect to available therapeutic options, there 
is a lack of consensus on treatment of MS with the 
recommended treatment regimen being conventional 
AML type chemotherapeutic protocols [1]. The role 
of radiotherapy in addition to chemotherapy is not well 
established with many studies showing no additional 
benefit [63, 64]. Other therapeutic modalities include 
hematopoietic stem cell transplantation and targeted 
therapy [1]. The prognosis of patients with MS is usu-
ally poor with slightly better outcomes when compared 
to primary or relapsed AML without extramedullary 
involvement. MS accompanying chronic myeloid  leuke-
mia or myelodysplastic syndrome is said to have a worse 
clinical outcome when compared to MS with AML.
To conclude, intraoral MS is a rare tumor with poor 
clinical outcome. It has protean clinical manifestations 
and histological overlap with numerous tumors making 
it a diagnostic challenge for clinicians and pathologists 
alike. When evaluating a tumor of unknown etiology, 
it is wise to maintain a high degree of suspicion espe-
cially if common antibody panels are negative for epi-
thelial, mesenchymal or lymphoid markers. Apart from 
immunohistochemistry, use of ancillary techniques 
such as cytogenetics and bone marrow examination 
may assist in diagnosing. Arriving at prompt accurate 
diagnosis facilitates timely and effective therapeutic 
intervention thus improving patient outcomes.
Conflict of interest: Nil.
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